Slide 1: Grow with Ginkgo H1 Revenue Update & Business Review
Grow with Ginkgo H1 Revenue Update & Business Review August 18, 2021 GI N KGO B I O W OR K S H1 U P D A T E | A U GU S T 2 0 2 1Grow with Ginkgo H1 Revenue Update & Business Review August 18, 2021 GI N KGO B I O W OR K S H1 U P D A T E | A U GU S T 2 0 2 1
Slide 2: Disclaimer: Forward-Looking Statements
DISCLAIMER Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the federal securities laws, including statements with respect to the proposed business combination (the “Business Combination”) between Ginkgo Bioworks, Inc. (“Ginkgo”) and Soar
Slide 3: Our Mission: Make biology easier to engineer
Our Mission Make biology easier to engineer 3 GI N KGO B I O W OR K S H1 U P D A T E | A U GU S T 2 0 2 1Our Mission Make biology easier to engineer 3 GI N KGO B I O W OR K S H1 U P D A T E | A U GU S T 2 0 2 1
Slide 4: We believe…
We believe… 1 2 3 Cell programming is Downstream value will Delta sucks. And so will the next thing. starting to become become more valuable than mainstream. Foundry service revenue. We have increased our 2021 Foundry service revenue de-risks Biosecurity will be a new market outlook for number of ne
Slide 5: Recent Highlights
Recent Highlights New +11 new programs in H1 Programs (+3 from existing customers) Program Successes (1) $400M+ state contracts for K-12 testing Biosecurity 1,000+ schools served Reshma Kewalramani (CEO Announced acquisition of of Vertex) announces she Other Highlights Dutch DNA (closed 7/1) will jo
Slide 6: Agenda
AGENDA H1 Revenue Update & Full Year Outlook Investor Presentation Supplement The Market for Cell Programming Downstream Value and Program Updates Biosecurity Q&A 6 GI N KGO B I O W OR K S H1 U P D A T E | A U GU S T 2 0 2 1AGENDA H1 Revenue Update & Full Year Outlook Investor Presentation Supplemen
Slide 7: Agenda
AGENDA H1 Revenue Update & Full Year Outlook Investor Presentation Supplement Q&A 7 GI N KGO B I O W OR K S H1 U P D A T E | A U GU S T 2 0 2 1AGENDA H1 Revenue Update & Full Year Outlook Investor Presentation Supplement Q&A 7 GI N KGO B I O W OR K S H1 U P D A T E | A U GU S T 2 0 2 1
Slide 8: H1 Revenue Update (Unaudited)
H1 Revenue Update (Unaudited) $Ms FY 6mo ended June 30, 2020 2020 2021 % YoY New Programs Launched 18 9 11 22% GAAP Revenue: Foundry $59 $31 $44 41% Biosecurity $17 -- $44 NM Total Revenue $77 $31 $88 180% 8 GI N KGO B I O W OR K S H1 U P D A T E | A U GU S T 2 0 2 1H1 Revenue Update (Unaudited) $Ms
Slide 9: Full Year Outlook (Unaudited)
Full Year Outlook (Unaudited) $Ms FY 6mo ended June 30, 2021 FY Outlook % Change In 2021 2021 Updated 2020 2020 2021 % YoY Original Updated Outlook vs. 2020A New Programs Launched 18 9 11 22% 23 30 30% 67% GAAP Revenue: Foundry $59 $31 $44 41% $100 $100 - 69% (1) Biosecurity $17 -- $44 NM $50 $75+ 5
Slide 10: Agenda
AGENDA H1 Revenue Update & Full Year Outlook Investor Presentation Supplement The Market for Cell Programming Downstream Value and Program Updates Biosecurity Q&A 10 GI N KGO B I O W OR K S H1 U P D A T E | A U GU S T 2 0 2 1AGENDA H1 Revenue Update & Full Year Outlook Investor Presentation Suppleme
Slide 11: Major customer programs across diverse industries have run on our platform
From May 2021 Investor Presentation Over 70 major customer programs across diverse industries have run on our platform through 2020 = DIVERSIFIED Cumulative Major 3rd Party Programs PLATFORM Can respond rapidly to 80 emerging opportunities and global threats + PHARMA & BIOTECH Mammalian capabilities
Slide 12: Programs drive predictable near-term revenues and long-term value creation
From May 2021 Investor Presentation Programs drive both predictable near-term revenues and long-term value creation with asymmetric upside potential Foundry Downstream Value Upfront payments to cover R&D Value sharing via customer equity and/or costs for customer programs royalties on completed prog
Slide 13: Ginkgo taps into two distinct addressable markets
From May 2021 Investor Presentation Thus, Ginkgo taps into two distinct addressable markets: one for the R&D itself (Foundry Revenue) and one for the products enabled (Downstream Value) Market for Cell Programming R&D Emerging Market for Products Enabled 2030—2040 Annual Direct Economic Impact By Do
Slide 14: Credibility across end-markets is driving inbound interest and new program launches
Ginkgo’s credibility across end-markets is driving inbound interest and accelerating the pace of new program launches 19 New Programs Large market for cell programming R&D across segments 30 Expected for H2 30 Increasing annual Market Mature Companies Startups (1) Organizational focus and Leapfrog i
Slide 15: Agenda
AGENDA Investor Presentation Supplement Downstream Value and Program Updates H1 UPDATE | AUGUST 2021 GINKGO BIOWORKS 3 a
Slide 16: Diversity in downstream value structures
Diversity in downstream value structures, some being realized today Milestones Lump-sum payment upon the achievement of specified criteria Royalties Royalties based on sales of end products (structures can vary: percent of revenue, cost of goods sold, etc.) Case studies generating value today: 1 2 G
Slide 17: Case Study: Cronos programs
CASE STUDY Ginkgo is developing 8 molecules for Cronos through two major programs, the first of which is expected to be commercialized this year CRONOS OUP “At this stage, we have all the necessary licenses to commercialize a product using cultured cannabinoids produced in our Winnipeg facility and
Slide 18: Cronos programs contribute Foundry Revenue and Equity-Based Milestones
CASE STUDY | Cronos programs contribute both Foundry Revenue and Equity-Based Commercial Milestones CRONOS GROUP x 3 “ Foundry Sn Downstream Value tm un > ° > . < Program Stage Falcone cha = $22M total Foundry Revenue Cronos has reported u Active Pi Hi: budgeted across 2 major programs ial they expe
Slide 19: New partnership with Aldevron has potential to generate near-term royalties
New partnership with Aldevron has potential to generate substantial near-term royalties mRNA Supply Chain is Expanding Moderna and Pfizer/BioNTech have paved the way for future mRNA therapeutic growth * Modality yields faster time to market and strong performance * Pfizer + Moderna are expected to p
Slide 20: Aldevron partnership downstream value
CASE stupy D New partnership with Aldevron has potential to generate substantial near-term royalties taldevron Sn Downstream Value Ginkgo receives a royalty on sales, in a tiered structure with rates increasing as process Ginkgo conducted VCE R&D improvements are achieved. wo pro-Pene up, With break
Slide 21: Motif FoodWorks multi-program collaboration
Motif FoodWorks, which has a multi-program collaboration with Ginkgo, launching first major products this year CASE STUDY 3 The Boston Globe Ginkgo’s spinout Motif to release plant-based meat tech after raising $226 million yd ay ee aive@ The Mott out fod sinc sb. MOTE FOODNORKS Number Active Progra
Slide 22: Motif contributes Foundry Revenue and downstream value in equity
Motif contributes both Foundry Revenue and downstream value in the form of equity, which has seen substantial appreciation as + $25 $20 $19M Foundry Revenue ($M) 2019 2020 Foundry revenue generated across a number of discrete programs FOOD Downstream Value AGFUNDER Motif Ingredients Raises $90m Seri
Slide 23: Agenda: Biosecurity
AGENDA Investor Presentation Supplement Biosecurity H1 UPDATE | AUGUST 2021 GINKGO BIOWORKS o N oO
Slide 24: K-12 statewide testing contracts
NATIONAL Biden Administration to Invest More Than $12 RATEGY Billion to Expand COVID-19 Testing THE COVID-19 RESPONSE AND PANDEMIC Publicly Announced Major Contracts Testing Ramp-Up Is Part of Biden's Overall Etfort to Increase Testing Nationwide as Vaccinations Increase PREPAREDNESS Preparedness -
Slide 25: Biosecurity will be a permanent fixture in our lives
School testing is an emergent need, but we believe biosecurity will be a permanent fixture in our lives Broad Endpoint Coverage De wa OF ss Surveillance: monitoring, looking for new threats Scale Number of noses, hospitals, farms, fields, labs, and sewage systems ¢ = ox os oa ae i] Oo Robust Threat
Slide 26: Responsibility to be at the forefront of emerging biosecurity industry
Ginkgo has a responsibility to be at the forefront of the emerging biosecurity industry Eons Q sown Bloomberg The DNA Cops Who Make Sure the World’s Deadliest Viruses Aren’t Rebuilt Ginkgo Bioworks is helping stop a new class of lethal biological weapons from being created. Rebecca Spalaing “We are
Slide 27: We believe...
We believe... 1 Cell programming is starting to become mainstream. We have increased our 2021 outlook for number of new programs from 23 to 30 due to higher-than-expected inbound interest from potential customers and enhanced credibility from completing programs. 2 Downstream value will become more
Slide 28: Agenda: Q&A
AGENDA Lzoz Lsnonvw | ALvGdn LH Q&A SYYOMOIG ODANID 2
Slide 29: Appendix
APPENDIX 29APPENDIX 29
Slide 30: Additional Legal Information
ADDITIONAL LEGAL INFORMATION Forward-Looking Statements Legend This document contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Ginkgo and Soaring Eagle, including statements regarding the anticipated timing